Feb 8, 2023 05:00PM
Feb 6, 2023 05:00PM
Feb 1, 2023 05:00PM
Jan 31, 2023 05:00PM
Jan 12, 2023 07:30AM
Nov 8, 2022 05:30PM
Nov 2, 2022 08:00AM Medexus Schedules Second Quarter 2023 Conference Call
Oct 6, 2022 07:30AM
Sep 29, 2022 05:05PM
Sep 19, 2022 08:00AM
Sep 15, 2022 05:05PM
Aug 8, 2022 05:00PM
Aug 2, 2022 05:00PM
Jul 25, 2022 07:00AM Treosulfan NDA Resubmitted to FDA
Jun 22, 2022 05:50PM
Jun 14, 2022 04:30PM
Jun 6, 2022 08:30AM
May 24, 2022 05:05PM
Apr 22, 2022 08:30AM
Apr 19, 2022 04:20PM
Mar 9, 2022 08:00AM Medexus to Participate in the 34th Annual Roth Conference
Mar 1, 2022 07:15AM
Feb 14, 2022 08:00AM
Feb 9, 2022 06:30PM
Feb 1, 2022 04:15PM
Jan 31, 2022 08:00AM
Dec 2, 2021 08:08AM
Nov 10, 2021 05:00PM Medexus Pharmaceuticals Reports Financial and Operational Results for the Three- and Six-Month Periods Ending September 30, 2021
Nov 1, 2021 09:27AM
Sep 21, 2021 06:09PM
Aug 16, 2021 05:30PM
Aug 12, 2021 07:30AM
Aug 4, 2021 10:58AM
Aug 3, 2021 07:45AM
Jul 12, 2021 09:29AM Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in Canada
Jun 28, 2021 04:30PM
Jun 16, 2021 05:00PM
Jun 10, 2021 08:30AM
Jun 9, 2021 08:30AM
Mar 1, 2021 05:00PM
Feb 2, 2021 02:21PM
Dec 18, 2020 08:30AM Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH) in the United States with Ethypharm
Nov 16, 2020 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All